2022 is a milestone year for DOSIsoft - Leading provider of Patient-specific software solutions for Radiation Oncology and Nuclear Medicine - celebrating its 20-year-involvement in delivering innovation for cancer care worldwide.
20-year-commitment: one vision, same identity
Spin-off between Gustave Roussy and Institut Curie, the 2 reference Cancer Treatment centers in France and Europe, DOSIsoft was created in 2002, as a family-owned start-up, under the management and leadership of Hanna Kafrouni, PhD, starting from a simple, entrepreneurial, and engineering idea: “providing Dosimetry Software Solutions” for radiation therapy (RT), as meant by its logo DOSIsoft.
Time goes on; even though healthcare landscape changes and cancer patient concerns evolve, its ambition remains to help RT professionals deliver safe, efficient & personalized Cancer Treatments. Guided by the initial spirit and leveraging its strong medical imaging, dosimetry & digital expertise, DOSIsoft is now recognized as a key player in the dosimetry market.
20-year-innovation: one mission, global expansion
Constantly improved over 20 years, its cutting-edge solutions offer exclusive and distinctive features in patient diagnosis, treatment planning, dose computation, quality assurance and cancer disease follow-up. They matured through collaborations with a unique network of leading academic, scientific and clinical partners in France and Europe, and through several ambitious collaborative projects in IT, Digital technologies, Radiation Therapy and Nuclear Medicine.
Today, two flagship product lines – ThinkQA (Patient Quality Assurance for RT) and PLANET® (Molecular Imaging & RadioTherapy) – have been adopted successfully by over 300 hospital centers in 50 countries throughout the world, thanks in particular to its recent global industry partnership with Elekta on Patient-QA software solutions.
20-year-success: one team, bright future
The past 20 years were full of exciting events, unexpected outcomes, sometimes risky & difficult moments. What makes DOSIsoft successful is its highly experienced and qualified team – today, over 45 talented people working in two offices based in France and USA.
“DOSIsoft can be proud of its success and share it with its customers, partners, shareholders and employees” said Marc Uszynski, current CEO of DOSIsoft. “The years to come would be another adventure full of innovations, still dedicated to improving cancer treatments tailored for each patient.”
"For 100 years, Gustave Roussy has worked to accelerate access to innovation for cancer patients. It's in the DNA of our institution," said Professor Fabrice Barlesi, CEO of Gustave Roussy. "Our partnership within DOSIsoft is part of this tradition by allowing us to leverage the best technological solutions in all areas of oncology for better quality and reliability of care,”
"It is with great satisfaction that I join the 20th anniversary of DOSIsoft, the first start-up that was ever created by Institut Curie. Over the years, a multitude of collaborations have been established around innovation in radiotherapy, a key therapeutic issue for Institut Curie, the leading center in France thanks in particular to a unique technical platform that is among the most efficient in Europe. 20 years later, I am impressed by the path taken by DOSIsoft and its dazzling success, put at the service of an ambition that I share: to continue to innovate in order to provide patients with new treatments to fight cancer effectively. Finally, this longevity reflects the solidity of Institut Curie’s innovations and the importance of putting them at the service of the creation of companies that will bring these cutting-edge technologies to all patients,” explains Prof. Steven Le Gouill, Director of Institut Curie Hospital Group.
About DOSIsoft - Founded in 2002, DOSIsoft designs, develops & delivers patient-specific imaging & dosimetry software solutions in Radiation Oncology & Nuclear Medicine to improve cancer patient safety & treatment quality. 20 years of innovation and R&D investments have led to world leading software used in over 300 hospital centers in 50 countries. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world. www.dosisoft.com
About Gustave Roussy - Ranked as the leading European Cancer Centre and sixth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials. https://www.gustaveroussy.fr
About Institut Curie - Institut Curie, France’s leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs 3,700 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud and Orsay), working on its three missions: treatment, research, and teaching. A private foundation with public utility status, Institut Curie is authorized to receive donations and legacies, and thanks to the support of its donors, is able to make discoveries more quickly, improving treatments and quality of life for patients. Find out more: www.curie.fr
Since 2011, Institut Curie has been certified “Carnot Curie Cancer”. The Carnot certification is a recognition of excellence awarded to academic research organizations whose quality and involvement in partnership-based research have been demonstrated. Curie Cancer offers industrial partners the opportunity to implement research collaborations utilizing the expertise of Institut Curie’s research teams to develop innovative therapeutic solutions for cancer, from therapeutic target to clinical approval. Curie Cancer is a member of the Carnot FINDMED network, a group of thirteen Carnot institutes, to facilitate access to their technological platforms and to their innovations for very small and medium-sized companies in the pharmaceutical industry. Find out more: http://www.instituts-carnot.eu/fr/institut-carnot/curie-cancer - https://findmed.fr